Skip to main content

Ironwood Pharmaceuticals, Inc.

corporate_fare Company Profile

Ironwood Pharmaceuticals, Inc.

IRWD·NASDAQ·Life Sciences·CIK 0001446847

Our Company is a biotechnology company that develops and sells therapies for people with gastrointestinal (GI) and rare diseases. We focus on creating and commercializing innovative products in areas where there is a significant unmet medical need, using our expertise in GI and rare diseases. Our commercial product, LINZESS® (linaclotide), is the first U.S. FDA-approved guanylate cyclase type C (GC-C) agonist. In the U.S., LINZESS is indicated for irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation (CIC) in adults, and functional constipation (FC) in pediatric patients ages 6-17 years-old. LINZESS is also available for adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is sold as CONSTELLA® in Canada for adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC, and to adults with IBS-C in certain European countries. We have strategic partnerships with pharmaceutical companies to develop and commercialize linaclotide globally, including with AbbVie Inc. in the U.S. and all countries worldwide except China (including Hong Kong and Macau) and Japan, AstraZeneca AB in China (including Hong Kong and Macau), and Astellas Pharma Inc. in Japan. Following our acquisition of VectivBio Holding AG in June 2023, we are developing apraglutide, a next-generation, synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS) patients who rely on parenteral support (PS).

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for IRWD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Ironwood Pharmaceuticals Confirms Revolving Credit Facility Maturity Date by Meeting Liquidity Conditions
  • Annual Report Details Major Restructuring, R&D Setbacks, and Medicare Pricing Impact Despite Improved Net Income
  • Ironwood Pharmaceuticals Reports Strong 2026 Outlook with Significant Revenue & EBITDA Growth, Advances Key Pipeline Asset

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$296.15M
Net Income
$24.02M
Diluted EPS
$0.15
Op. Cash Flow
$127.04M
Free Cash Flow
$127.01M
Operating Income
$98.5M
Cash & Equivalents
$215.46M
Debt / Equity
0.00×
Net Margin
8.1%
Shares Outstanding
163.06M sh
Source: 10-K · filed 2026-02-26 · accession 0001104659-26-020489
$4.6 -2.13% today
52-week range · as of 2026-11-05 $1.88 – $5.78
Market cap
$778.09M
Volume
3M (1.3× avg)
3-mo avg 2.4M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IRWD - Filings & News (Page 2)

IRWD
Mar 11, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $4.60 info
Change: +$0.890 (+24%) info
Market Cap: $778.089M info
IRWD
Feb 26, 2026, 4:09 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.66
Real-time Price: $4.60 info
Change: +$0.940 (+26%) info
Market Cap: $778.089M info
IRWD
Feb 25, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.44
Real-time Price: $4.60 info
Change: +$1.16 (+34%) info
Market Cap: $778.089M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets